Rituximab therapy for type I membranoproliferative glomerulonephritis

Clinical Nephrology

Volumn 77, Issue 4, 2012, Pages 290-295

  Dillon, John J ^a   Hladunewich, Michelle ^b   Haley, William E ^c   Reich, Heather N ^b   Cattran, Daniel C ^b   Fervenza, Fernando C ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

CD20; Immunosuppression; Membranoproliferative glomerulonephritis; Monoclonal antibodies; Proteinuria

Indexed keywords

DIPHENHYDRAMINE; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANADA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; OPEN STUDY; PROTEINURIA; REMISSION; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CANADA; CRYOGLOBULINEMIA; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; TREATMENT OUTCOME; UNITED STATES;

EID: 84861493758     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107299     Document Type: Article

References (33)

1. Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 2006; 69: 504-511. doi:10.1038/sj.ki.5000084 PubMed
2. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone-a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992; 6: 123-130. doi:10.1007/BF00866289 PubMed
3. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore). 2002; 81: 398-409. doi:10.1097/00005792-200209000-00005 Pub Med
4. Boseman P, Lewin M, Dillon J, Sethi S. Marfan syndrome, MPGN, and bacterial endocarditis. Am J Kidney Dis. 2008; 51: 697-701. doi:10.1053/j. ajkd.2007.08.031 PubMed
5. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999; 106: 347-354. doi:10.1016/S0002-9343(99)00014-5 Pub Med
6. Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, Nadasdy T, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009; 20: 2055-2064. doi:10.1681/ASN.2009010110 PubMed
7. Silva F. Membranoproliferative glomerulonephritis. In: Heptinstall R (ed). Pathology of the Kidney. Boston/Toronto/London: Little, Brown and Company; 1992. p. 477-557.
8. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73: 117-125. doi:10.1038/sj.ki.5002628 PubMed
9. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54: 613-620. doi:10.1002/art.21617 PubMed
10. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 2377-2386. doi:10.1002/art.22019 PubMed
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (Suppl 1): 1-266. PubMed
12. Donadio JV Jr, Anderson CF, Mitchell JC III, Holley KE, Ilstrup DM, Fuster V, Chesebro JH. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med. 1984; 310: 1421-1426. doi:10.1056/NEJM198405313102203 PubMed
13. Donadio JV Jr, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis. 1989; 14: 445-451. PubMed
14. Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int. 1985; 27: 436-441. doi:10.1038/ki.1985.28 PubMed
15. Zäuner I, Böhler J, Braun N, Grupp C, Heering P, Schollmeyer P; Collaborative Glomerulonephritis Therapy Study Group (CGTS). Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrol Dial Transplant. 1994; 9: 619-622. PubMed
16. Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant. 2004; 19: 3160-3164. doi:10.1093/ndt/gfh526 PubMed
17. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113: 4834-4840. doi:10.1182/blood-2008-10-186999 PubMed
18. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350: 2572-2581. doi:10.1056/NEJMoa032534 PubMed
19. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66: 460-471. doi:10.1002/ana.21867 PubMed
20. Glassock RJ, Cohen AH, Adler S. G. Primary Glomerular Diseases. In: Brenner BM (ed). Brenner and Rector's The Kidney. Fifth edn. Philadelphia: W. B. Saunders; 1996. p. 1392-1497.
21. Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation. 2005; 80: 1560-1564. PubMed doi:10.1097/01.tp.0000183749.79424.b4
22. Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc. 2006; 38: 2308-2310. doi:10.1016/j.transproceed.2006. 06. 131 PubMed
23. Bestard O, Cruzado JM, Ercilla G, Gomà M, Torras J, Serón D, Rama I, Ibernon M, Viñas O, Carrera M, Grinyó JM. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant. 2006; 21: 2320-2324. doi:10.1093/ndt/gfl266 PubMed
24. Braun A, Neumann T, Oelzner P, Hein G, Gröne HJ, Ziemer M, Wolf G. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol Int. 2008; 28: 503-506. doi:10.1007/s00296-007-0462-y PubMed
25. Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008; 42: 862-863. doi:10.1097/MCG.0b013e3180f60b7a PubMed
26. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis. 2004; 43: 34-38. doi:10.1053/j.ajkd.2003.12.057 PubMed
27. Korte MR, van Heerde MJ, de Man RA, Betjes MH. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia. Neth J Med. 2008; 66: 27-30. PubMed
28. Pandrangi S, Singh A, Wheeler DE, Rossi NF. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Clin Pract Nephrol. 2008; 4: 393-397. doi:10.1038/ncpneph0823 PubMed
29. Quartuccio L, Salvin S, Fabris M, Sacco S, De Vita S. Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. Ann Rheum Dis. 2008; 67: 1494-1495. doi:10. 1136/ard.2007.084939 PubMed
30. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford). 2006; 45: 842-846. doi:10.1093/rheumatology/kel004 PubMed
31. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, Mazzucco G, Sena LM. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2004; 19: 3054-3061. doi:10.1093/ndt/gfh469 PubMed
32. Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, Fiorilli M, Casato M. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol. 2007; 125: 30-33. doi:10.1016/j.clim.2007.06.008 PubMed
33. Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ, Yasenchak CA, Kumar SK, Gertz MA. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma. 2006; 7: 140-144. doi:10.3816/CLM .2006.n.052 PubMed